As August draws to a close, let us reflect on some of the regulatory news that made headlines in the month and look ahead to what September has in store.
Adaptimmune Therapeutics plc's (ADAP) Tecelra was granted accelerated approval by the FDA on Aug.1, 2024, for the treatment of adults with unresectable or metastatic synovial sarcoma, a rare form of cancer, becoming the first new treatment option for this disease in more than a decade. It also represents the first gene therapy for metastatic synovial sarcoma.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com